S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(2.16%) $83.11
Gas
(1.98%) $1.752
Gold
(1.90%) $2 254.80
Silver
(1.41%) $25.10
Platinum
(1.45%) $922.85
USD/EUR
(0.36%) $0.927
USD/NOK
(0.76%) $10.85
USD/GBP
(0.10%) $0.792
USD/RUB
(0.13%) $92.56

Realtime updates for Biogen Inc [BIIB]

Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturersā€”General
BUY
56.25%
return -5.38%
SELL
40.63%
return 6.58%
Last Updated28 Mar 2024 @ 16:00

-0.33% $ 215.63

SELL 1667 min ago

@ $215.09

Issued: 27 Mar 2024 @ 14:24


Return: 0.25%


Previous signal: Mar 27 - 13:42


Previous signal: Buy


Return: 0.33 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):
Our systems believe the stock currently is overvalued by 0.14% compare to its pairs and should correct downwards.
Profile picture for Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis...

Stats
Today's Volume 1.76M
Average Volume 1.16M
Market Cap 31.34B
EPS $0 ( 2024-02-13 )
Next earnings date ( $3.48 ) 2024-04-23
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 27.09
ATR14 $3.54 (1.64%)
Insider Trading
Date Person Action Amount type
2024-02-22 Singhal Priya Sell 262 Common Stock
2024-02-16 Alexander Susan H Buy 3 423 Common Stock
2024-02-16 Alexander Susan H Buy 1 614 Common Stock
2024-02-16 Alexander Susan H Sell 781 Common Stock
2024-02-16 Alexander Susan H Sell 1 656 Common Stock
INSIDER POWER
7.53
Last 100 transactions
Buy: 88 430 | Sell: 75 725
Correlation (AI algo v.1.1b): Overvalued: -0.14% $215.34 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.67 (moderate)
Short: 0.45 (neutral)
Signal:(54) Neutral

Biogen Inc Correlation

10 Most Positive Correlations
EVCM0.883
RBNC0.879
NLTX0.879
ACLX0.878
EGRX0.873
ARCT0.865
HBIO0.863
NATI0.862
FCFS0.861
MDLZ0.858
10 Most Negative Correlations
NYMTN-0.908
WTRE-0.908
RNMC-0.903
REIT-0.903
KBWD-0.9
SDVY-0.899
NEOG-0.899
FFBW-0.898
XT-0.895
ICHR-0.895

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biogen Inc Correlation - Currency/Commodity

The country flag 0.42
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.48
( neutral )
The country flag -0.47
( neutral )
The country flag -0.71
( moderate negative )

Biogen Inc Financials

Annual 2023
Revenue: $9.84B
Gross Profit: $7.30B (74.24 %)
EPS: $8.02
Q4 2023
Revenue: $2.39B
Gross Profit: $1.77B (74.09 %)
EPS: $1.720
Q3 2023
Revenue: $2.53B
Gross Profit: $1.87B (73.93 %)
EPS: $-0.470
Q2 2023
Revenue: $2.46B
Gross Profit: $1.86B (75.87 %)
EPS: $4.09

Financial Reports:

No articles found.

Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators